The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity

Vaccine

Volumn 16, Issue 2-3, 1998, Pages 208-215

  Hurpin, Christian ^a   Rotarioa, Chantal ^a   Bisceglia, Hélène ^a   Chevalier, Michel ^a   Tartaglia, James ^b   Erdile, Lorne ^a,b  

^a Pasteur Mérieux Connaught ^*  (France)

^b Virogenetics Inc   (United States)

Author keywords

CTL; Tumor associated antigen; Vaccination

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLASMID DNA; PROTEIN P53; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; REGIONAL PERFUSION; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR; VACCINATION; VIRUS RECOMBINANT;

ANIMALS; CANCER VACCINES; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; FEMALE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; VACCINES, DNA;

EID: 0031986115     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00190-4     Document Type: Article

References (39)

1. MN env gene. J. Infect. Dis. 1995, 171, 1623-1627.
2. 2 Fleury, B., Janvier, G., Pialoux, G., Buseyne, F., Robertson, M.N., Tartaglia, J., Paoletti, E., Kieny, M.P., Excler, J.L. and Rivière, Y. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J. Infect. Dis. 1996, 174, 734-738.
3. 3 Fries, L.F., Tartaglia, J., Taylor, J., Kauffman, E.K., Meignier, B., Paoletti, E. and Plotkin, S. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996, 5, 428-434.
4. 4 Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Feigner, P.L., Dwarki, V.J., Gromkowski, S.H., Deck, R.R., DeWitt, C.M., Friedman, A., Hawe, L.A., Leander, K.R., Martinez, D., Perry, H.C., Shiver, J.W., Montgomery, D.L. and Liu, M.L. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259, 1745-1749.
5. 5 Boyer, J.D., Ugen, K.E., Wang, B., Agadjanyan, M., Gilbert, L., Bagarazzi, M.L., Chattergoon, M., Frost, P., Javadian, A., Williams, W.V., Refaeli, Y., Ciccarelli, R.B., McCallus, D., Coney, L. and Weiner, D. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 1997, 3, 526-532.
6. 6 Wang, M., Bronte, V., Chen, P.W., Gritz, L., Panicali, D., Rosenberg, S.A. and Restifo, N.P. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 1995, 154, 4685-4692.
7. 7 Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E. and Levine, A.J. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl, Acad. Sci. USA 1996, 93, 4781-4786.
8. 8 Conry, R.M., LoBuglio, A.F., Kantor, J., Schlom, J., Lochel, F., Moore, S.E., Sumerel, L.A., Barlow, D.L., Abrams, S. and Curiel, D.T. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res. 1994, 54, 1164-1168.
9. 9 Conry, R.M., LoBuglio, A.F., Lochel, F., Moore, S.E., Sumerel, L.A., Barlow, D.L. and Curiel, D.T. A carcinoembryonic antigen polynucleotide vaccine has in vivo tumor activity. Gene Ther. 1994, 2, 59-65.
10. 10 Irvine, K.R., Rao, J.B., Rosenberg, S.A. and Restifo, N.P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 1996, 156, 238-245.
11. 11 Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. p53 mutations in human cancers. Science 1991, 253, 49-53.
12. 12 Finlay, C.A., Hinds, P.W., Tan, T.-H., Eliyahu, D., Oren, M. and Levine, A.J. Activating mutations for transfromation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol. 1988, 8, 531-539.
13. 13 Iggo, R., Gatter, K., Bartek, J., Lane, D. and Harris, A.L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990, 335, 675-679.
14. 14 Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F. and Soussi, T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to mutational hot spot. Cancer Res. 1992, 52, 6380-6384.
15. 15 Lubin, R., Schlichtholz, B., Bengoufa, D., Zalcman, G., Trédaniel, J., Hirsch, A., Caron de Fromentel, C., Preudhomme, C., Fenaux, P., Fournier, G., Mangin, P., Laurent-Puig, P., Pelletier, G., Schlumberger, M., Desgrandchamps, F., Le Duc, A., Peyrat, J.P., Janin, N., Bressac, B. and Soussi, T. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 1993, 53, 5872-5876.
16. 16 Schlichtholz, B., Trédaniel, J., Lubin, R., Zalcman, G., Hirsch, A. and Soussi, T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer 1994, 69, 809-816.
17. 17 Tilkin, A.-F., Lubin, R., Soussi, T., Lazar, V., Janin, N., Mathieu, M.-C., Lefrère, I., Carlu, C., Roy, M., Kayibanda, M., Bellet, D., Guillet, J.-G. and Bressac-de Paillerets, B. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol. 1995, 25, 1765-1769.
18. 18 Houbiers, J.G.A., Nijman, H.W., van der Burg, S.H., Drijfhout, J.W., Kenemans, P., van de Velde, C.J.H., Brand, A., Momburg, F., Kast, W.M. and Melief, C.J.M. In vitro induction of human cytotoxic T lymphocyte responses against petides of mutant and wild-type p53. Eur. J. Immunol. 1993, 23, 2072-2077.
19. 19 Nijman, H.W., van der Burg, S.H., Vierboom, M.P.M., Houbiers, J.G.A., Kast, W.M. and Melief, C.J.M. p53, a poten-tial target for tumor-directed T cells. Immunol. Letts 1994, 40, 171-178.
20. 20 Röpke, M., Regner, M, and Claesson, M.H. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol. 1995, 42, 98-103.
21. 21 Röpke, M., Hald, J., Guldberg, P., Zeuthen, J., Nørgaard, L., Fugger, L., Svejgaard, A., van den Burg, S., Nijman, H.W., Melief, C.J.M. and Claesson, M.H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA 1996, 93, 14704-14707.
22. 22 Theobald, M., Biggs, J., Dittmer, D., Levine, A.J. and Sherman, L.A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 1995, 92, 11993-11997.
23. + cytotoxic T-cells. Cancer Res. 1993, 53, 3257-3261.
24. + T cells. Proc. Natl. Acad. Sci. USA 1994, 91, 3171-3175.
25. 25 Ciernik, I.F., Berzofsky, J.A. and Carbone, D.P. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 1996, 156, 2369-2375.
26. 26 Mayordomo, J.I., Loftus, D.J., Sakamoto, H., De Cesare, C.M., Appasamy, P.M., Lotze, M.T., Storkus, W.J., Appella, E. and DeLeo, A.B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 1996, 183, 1357-1365.
27. 27 Bertholet, S., Iggo, R. and Corradin, G. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur. J. Immunol. 1997, 27, 798-801.
28. 28 Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.C., Cox, W.I., Davis, S.W., Van der Hoeven, J., Meignier, B., Rivière, Y., Languet, B. and Paoletti, E. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992, 188, 217-232.
29. 29 Delphin, C., Cahen, P., Lawrence, J.J. and Baudier, J. Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high-affinity DNA binding and cysteine oxidation inhibits p53 DNA binding. Eur. J. Biochem. 1994, 223, 683-692.
30. 30 Morrissey, P.J., Bressler, L., Park, L.S., Alpert, A. and Gillis, S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol. 1987, 139, 1113-1119.
31. 31 Heufler, C., Koch, F. and Schuler, G. Granulocyte-macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans' cells into potent immunostimulatory cells. J. Exp. Med. 1988, 167, 700-705.
32. 32 Kündig, T.M., Bachmann, M.F., DiPaolo, C., Simard, J.J.L., Battegay, M., Lother, H., Gessner, A., Kühlcke, K., Ohashi, P.S., Hengartner, H. and Zinkernagel, R. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268, 1343-1344.
33. 33 Sato, Y., Roman, M., Tighe, H., Lee, D., Corr, M., Nguyen, M.-D., Silverman, G.J., Lotz, M., Carson, D.A. and Raz, E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273, 352-354.
34. 34 Yamamoto, S., Yamamoto, T., Shimada, S., Kuramoto, E., Kyano, O., Kataoka, T. and Tokunaga, T. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol, Immunol. 1992, 36, 983-997.
35. 35 Ballas, Z.K., Rasmussen, W.L. and Krieg, A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 1996, 157, 1840-1845.
36. 36 Stacey, K.J., Sweet, M.J. and Hume, D.A. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 1996, 157, 2116-2122.
37. 37 Klinman, D.M., Yi, A.-K., Beaucage, S.L., Conover, J. and Krieg, A.M. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. USA 1996, 93, 2879-2883.
38. 38 Haridas, V. and Saxena, R.K. Role of major histocompatibility complex class I antigens in modulating the performance of murine tumour cells in cold target competition assays. Immunology 1995, 84, 86-90.
39. 39 Soussi, T., Caron de Fromentel, C. and May, P. Structural aspects of the p53 protein in relation to gene evolution. Oncogens 1990, 5, 945-952.